Compare regulatory context
Compare the editorial record, not treatments. A status belongs to a specific product, route and indication. The categories below do not establish interchangeability, safety or suitability.
BPC-157
Research / no approved-treatment claimWhat FDA says about limited human safety information and compounding risks.
FDA lists BPC-157 among bulk substances whose nominations were withdrawn after placement in its category 2 interim-policy list. The agency identifies potential immunogenicity concerns and difficulties related to peptide impurities and active ingredient characterization.
The sports-medicine review describes mostly animal work; this is not established human injury treatment.
Primary regulatory or label source
Read complete evidence note
Tesamorelin
Prescription-product label contextThe EGRIFTA WR label describes a specific indication, not general weight-loss use.
The FDA-approved EGRIFTA WR label identifies tesamorelin as a growth hormone-releasing factor analog indicated to reduce excess abdominal fat in HIV-infected adults with lipodystrophy.
Read the complete note for product, route, evidence and safety limits.
Primary regulatory or label source
Read complete evidence note